Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 多克隆抗體
  4. RRM1 Antibody

RRM1 Antibody

  • 中文名稱：
    RRM1兔多克隆抗體
  • 貨號(hào)：
    CSB-PA236550
  • 規(guī)格：
    ￥1100
  • 圖片：
    • Gel: 10%SDS-PAGE, Lysate: 50 μg, Lane: Hela cells, Primary antibody: CSB-PA236550(RRM1 Antibody) at dilution 1/600, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds
  • 其他：

產(chǎn)品詳情

  • Uniprot No.：
  • 基因名：
    RRM1
  • 別名：
    R1 antibody; Ribonucleoside diphosphate reductase large subunit antibody; Ribonucleoside diphosphate reductase M1 chain antibody; Ribonucleoside diphosphate reductase subunit M1 antibody; Ribonucleoside reductase; large subunit antibody; Ribonucleoside-diphosphate reductase large subunit antibody; Ribonucleoside-diphosphate reductase subunit M1 antibody; Ribonucleotide reductase large chain antibody; Ribonucleotide reductase large subunit antibody; Ribonucleotide reductase M1 antibody; Ribonucleotide reductase M1 polypeptide antibody; Ribonucleotide reductase R1 subunit antibody; Ribonucleotide reductase; M1 subunit antibody; RIR 1 antibody; RIR1 antibody; RIR1_HUMAN antibody; RR 1 antibody; RR1 antibody; RRM 1 antibody; RRM1 antibody
  • 宿主：
    Rabbit
  • 反應(yīng)種屬：
    Human,Mouse
  • 免疫原：
    Fusion protein of Human RRM1
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated
  • 抗體亞型：
    IgG
  • 純化方式：
    Antigen affinity purification
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用范圍：
    ELISA,WB
  • 推薦稀釋比：
    Application Recommended Dilution
    ELISA 1:2000-1:5000
    WB 1:500-1:2000
  • Protocols：
  • 儲(chǔ)存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能：
    Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides.
  • 基因功能參考文獻(xiàn)：
    1. The evaluation of RRM1 gene expression in cfRNA allows for estimation of the risk of severe oral mucositis (OM) in patients subjected to radiotherapy PMID: 29865035
    2. The expression of RRM1 can be considered a predictor of poor survival in patients with pancreatic cancer receiving gemcitabine chemotherapy. PMID: 29214667
    3. Our results therefore demonstrate that RRM1 is a novel therapeutic target in multiple myeloma in the preclinical setting and provide the basis for clinical evaluation of RRM1 inhibitor, alone or in combination with DNA-damaging agents, to improve patient outcome in multiple myeloma PMID: 28442502
    4. three SNPs (corepressor interacting with RBPJ 1 (CIR1) rs13009079T>C, ribonucleotide reductase M1 (RRM1) rs1465952T>C and solute carrier family 38, member 4 (SLC38A4) rs2429467C>T), may play a role in the pathogenesis of lung cancer PMID: 27587543
    5. TP53 mutant cancer cells had elevation of ribonucleotide reductase subunit 1 (RRM1) and 2 (RRM2), which was reduced by inhibition of mTORC1. PMID: 28507282
    6. The genetic polymorphisms RRM1 -756T>C and -269C>A may not be a factor for susceptibility to cervical neoplasia PMID: 27179014
    7. Based on the results of clinical trials, we conclude that Ribonucleotide reductase (RR) enzymes (RR1 and RR2)inhibitors are viable treatment options, either as a monotherapy or as a combination in cancer chemotherapy. With the recent advances made in cancer biology, further development of RR inhibitors with improved efficacy and reduced toxicity is possible for treatment of variety of cancers. PMID: 28624910
    8. RRM1 single nucleotide polymorphism is associated with Non-Small-Cell Lung Cancer. PMID: 27908619
    9. RRM1/RRM2B enzyme is capable of retaining activity in hypoxia and therefore is favored over RRM1/RRM2 in order to preserve ongoing replication and avoid the accumulation of DNA damage in hypoxic cells. PMID: 28416140
    10. findings suggest that the up-regulated RRM1 and hTrx1 in colorectal cancer directly interact with each other and promote RR activity, resulting in enhanced DNA synthesis and cancer malignancy. PMID: 28411237
    11. RRM1 and ERCC1 expression levels did not show any relationship with overall survival. PMID: 26612755
    12. RRM1 and ERCC wild type alleles are risk-reducing factor for Coronary artery disease (CAD). Also, carrying RRM1 A allele might have a protective effect for smokers. PMID: 27566080
    13. Presence of rare AA (-37C>A) and CC (-524C>T) genotypes of the RRM1 may be favorable predictive factors for chemotherapy with platinum compounds and gemcitabine in non-small cell lung cancer patients. PMID: 26650486
    14. study finds that ERCC1 and RRM1 are not independent prognostic factors of recurrence in stage I non-small cell lung cancer patients PMID: 26542178
    15. mRNA expression of RRM1 was closely associated with cell proliferation and varied in seven non-Hodgkin lymphoma cell lines. PMID: 27173327
    16. A significant association has been found between RRM1 rs12806698 (-269C>A) RRM1 genotype and the risk for developing non-small cell lung cancer. PMID: 26718430
    17. Results underline the relevance of microRNA-101-3p-driven regulation of RRM1 in pancreatic ductal carcinoma gemcitabine resistance. PMID: 26828016
    18. The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer PMID: 26323924
    19. TUBB3, TOP2A, CYP19A1 and CYP2D6 gene expression, but not protein expression, was associated with patient survival. PMID: 26252353
    20. A possible predictive impact of ribonucleotide-reductase subunit-1 (RRM1) on vinorelbine efficacy in non-small cell lung cancer (NSCLC) has been previously reported. PMID: 26637889
    21. RRM1 expression was predictive and prognostic of clinical outcome in advanced UC treated with gemcitabine plus platinum combination chemotherapy PMID: 26200905
    22. RNA expression of deoxycytidine kinase (DCK), human equilibrative nucleoside transporter-1 (ENT1) and ribonucleotide reductase M1 (RRM1) were significantly higher and cytidine deaminase (CDA) was significantly lower in ex vivo Ara-C sensitive samples. PMID: 26083014
    23. It is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells. PMID: 25837929
    24. For RRM1 C37A-T524C genotype, sensitive group had higher proportion of high effective genotype than non-sensitive group (p=0.009). PMID: 26028097
    25. Adenoviral vector expressing short hairpin RNA targeting RRM1 exerts potent antitumor effects and increases sensitivity to gemcitabine. PMID: 26254808
    26. Data demonstrate that RRM1 gene interferes with mitotane metabolism in adrenocortical cancer cells, as a possible mechanisms of drug resistance. PMID: 25497672
    27. These in vitro results suggest that mRNA expression levels of the RRM1 and ABCB1 genes may be useful indicators of chemosensitivity to gemcitabine and cisplatin. PMID: 25560468
    28. The oligomerization-directed fluorescence quenching of hRNR-alpha, covalently labeled with two fluorophores, allows for direct readout of hRNR dimeric and hexameric states. PMID: 25256246
    29. RRM1 expression was identified as independent prognosticators for freedom from recurrence of malignant pleural mesothelioma in patients undergoing induction chemotherapy followed by extrapleural pneumonectomy. PMID: 25840756
    30. In Turkish population RRM1 rs12806698 carriers have nearly twofold risk for development of head and neck squamous epithelial cell cancer. PMID: 24861915
    31. Patients with high RRM1 expression benefited more from a platinum-containing regimen, and patients with high BRCA1 expression showed a high response rate to a platinum-containing regimen and reduced disease progression. PMID: 25078585
    32. Gene polymorphisms of RRM1 -756T>C and RRM1 -269C>A may be not an important factor for the susceptibility of breast cancer. PMID: 24578158
    33. concomitant low expression levels of ERCC1, RRM1, and RRM2 and the high expression level of BRCA1 were predictive of a better outcome. PMID: 25227663
    34. RRM1 gene expression may contribute to chemotherapy sensitivity and may be an indicator of survival in nonsmall cell lung cancer patients treated with gemcitabine plus cisplatin. PMID: 24591771
    35. RRM1 IHC expression tailored selection of first-line therapy could improve therapeutic outcomes in patients with advanced NSCLC. PMID: 24595080
    36. High intratumoural hENT1 and low RRM1 expression were independently associated with prolonged disease-free survival in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy. PMID: 25032731
    37. High RRM1 expression is associated with non-small cell lung cancer. PMID: 23803067
    38. No change in RRM1 expression was observed in primary NSCLC tumours, but expression seemed to be higher in N2 lymph node metastases following chemotherapy. PMID: 24266856
    39. Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer. PMID: 23922955
    40. we found no support of the hypothesis that aberrations of RRM1 or RRM2B, neither individually nor in combination, are associated with an altered clinical outcome following chemotherapy. PMID: 24215511
    41. We observed an increase of ORR in NSCLC patients when they were treated with chemotherapy according to ERCC1 and RRM1 SNPs status. PMID: 24045016
    42. low expression of RRM1 and RRM2 could be used to predict the treatment response to platinum-based chemotherapy and survival in non-small cell lung cancer PMID: 24155212
    43. RRM1 preserves chromosomal stability via the CHK1- and CDK1-dependent stabilization of the centrosomal integrity at the replication stage. PMID: 24434653
    44. Genetic polymorphisms in SLC28A3, SLC29A1 and RRM1 can influence the clinical outcome of metastatic breast cancer patients treated with paclitaxel-gemcitabine chemotherapy. PMID: 24361227
    45. The analysis of RRM1 (-37C>A) more than ERCC1 (19007C>T) polymorphism may be a promising tool in the qualification of NSCLC patients for chemotherapy containing platinum compounds and gemcitabine PMID: 23982437
    46. These results suggest that SNPs within ribonucleotide reductase (RRM1 and RRM2) might be helpful predictive markers of response to nucleoside analogs and should be further validated in larger cohorts. PMID: 24024897
    47. Low RRM1 expression is associated with response to therapy in pancreatic cancer. PMID: 23991987
    48. RR1 expression may discriminate cervical cancer phenotype and radiochemotherapy outcome PMID: 23552804
    49. The expressions of MDR-1, RRM-1, EGFR, ERCC-1 were observed in a variety of pathological types of NSCLC. PMID: 23948418
    50. Report essential roles for ribonucleotide reductase and thymidylate synthase in C-MYC-dependent suppression of senescence in melanoma cells. PMID: 23249808

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Cytoplasm.
  • 蛋白家族：
    Ribonucleoside diphosphate reductase large chain family
  • 數(shù)據(jù)庫(kù)鏈接：

    HGNC: 10451

    OMIM: 180410

    KEGG: hsa:6240

    STRING: 9606.ENSP00000300738

    UniGene: Hs.445705